Important: Semax is approved in Russia; supporting human trials are largely non-randomized and not independently replicated to Western standards.
Overview
Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the ACTH(4-7) fragment (Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro extension for metabolic stability. It is approved in Russia and Ukraine as a nootropic and neuroprotective agent, with clinical applications in stroke rehabilitation, cognitive impairment, and attention deficit disorders. Semax is distinguished from most nootropic compounds by its robust, well-characterized effect on brain-derived neurotrophic factor (BDNF) and its receptor TrkB — a neurotrophin signaling pathway that is central to synaptic plasticity, neurogenesis, and neuroprotection. Its mechanism is fundamentally different from stimulant-based cognitive enhancers, operating through neurotrophic rather than catecholaminergic pathways.
Mechanism of Action
Semax's primary mechanism involves upregulation of BDNF and its high-affinity receptor TrkB in the hippocampus, frontal cortex, and basal forebrain. BDNF/TrkB signaling activates the PI3K/Akt and MAPK/ERK pathways, promoting neuronal survival, synaptic plasticity (LTP), and neurogenesis in the hippocampal dentate gyrus — the cellular substrates of learning and memory. Semax also modulates the dopaminergic and serotonergic systems, increasing catecholamine turnover in the prefrontal cortex and limbic system. Additionally, it reduces neuroinflammation by suppressing NF-κB-mediated cytokine expression (IL-1β, TNF-α) in activated microglia, providing neuroprotective effects in ischemic and infl
Research Evidence
- Approved nootropic/neuroprotective agent in Russia and Ukraine for stroke and cognitive impairment
- Robust BDNF and TrkB upregulation in hippocampus and frontal cortex (Dolotov et al., 2006)
- Reduces cerebral infarct volume and improves functional recovery in stroke models
- Suppresses NF-κB-mediated neuroinflammation (IL-1β, TNF-α) in activated microglia
- Modulates dopaminergic and serotonergic systems in prefrontal cortex and limbic structures
Bottom line: Semax is a well-characterized nootropic peptide with approved clinical status in Russia for neurological conditions. Its BDNF-upregulating mechanism is grounded in solid neuroscience. Like Selank, its evidence base is primarily in the Russian literature, though the underlying biology (BDNF, NGF) is extensively validated in Western research. Research-only compound outside Russia.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Semax are detailed in the full compound profile. See also: Dosage guide for Semax.
Sourcing & Quality
Semax is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Semax at Purgo Labs.